NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.11 +4.01 (+26.56 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$15.10
Today's Range$15.03 - $19.19
52-Week Range$12.77 - $41.20
Volume15.05 million shs
Average Volume2.77 million shs
Market Capitalization$1.79 billion
P/E Ratio-8.06
Dividend YieldN/A
Beta3.64
ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Debt-to-Equity RatioN/A
Current Ratio6.12
Quick Ratio6.02

Price-To-Earnings

Trailing P/E Ratio-8.06
Forward P/E Ratio-9.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$124.90 million
Price / Sales19.13
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book7.08

Profitability

EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-135.99%
Return on Equity-78.56%
Return on Assets-68.75%

Miscellaneous

Employees425
Outstanding Shares125,010,000
Market Cap$1.79 billion

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.06. The biopharmaceutical company earned $57.06 million during the quarter, compared to analysts' expectations of $58.63 million. ACADIA Pharmaceuticals had a negative net margin of 135.99% and a negative return on equity of 78.56%. The company's revenue for the quarter was up 87.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.55) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for ACADIA Pharmaceuticals.

What price target have analysts set for ACAD?

12 brokers have issued 1-year price objectives for ACADIA Pharmaceuticals' stock. Their predictions range from $17.00 to $60.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $39.2727 in the next year. This suggests a possible upside of 105.5% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.

What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, "We are Overweight on ACAD with a 12-month PT of $25 based on NUPLAZID/ pimavanserin in PDP/other neuropsych indications. Our contrarian view is based on long-standing & recently updated pima’ diligence leading us to dismiss issues raised in the media that have challenged, albeit we believe temporarily, NUPLAZID sales & ACAD shares. Why? NUPLAZID remains the only agent approved for PDP against a class of atypical antipsych drugs used off-label with known safety challenges." (9/20/2018)
  • 2. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (9/10/2018)
  • 3. HC Wainwright analysts commented, "Valuation and risks to achievement of the target price. Our $60 PT is based on an equally weighted composite of: (a) $69/ share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing." (8/9/2018)

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
  • Mr. Todd S. Young, Exec. VP & CFO (Age 46)
  • Dr. Srdjan R. Stankovic, Exec. VP and Head of R&D (Age 61)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 56)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

News headlines about ACAD stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for ACADIA Pharmaceuticals.

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), BlackRock Inc. (7.80%), OppenheimerFunds Inc. (3.57%), Orbimed Advisors LLC (3.43%), Janus Henderson Group PLC (2.76%) and First Trust Advisors LP (2.09%). Company insiders that own ACADIA Pharmaceuticals stock include Daniel B Soland, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Fred Alger Management Inc., State Board of Administration of Florida Retirement System, Voya Investment Management LLC, Wealthstreet Investment Advisors LLC, California Public Employees Retirement System, Trexquant Investment LP and SG Americas Securities LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Orbimed Advisors LLC, First Trust Advisors LP, Northern Trust Corp, ING Groep NV, Los Angeles Capital Management & Equity Research Inc., Schwab Charles Investment Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $19.11.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $1.79 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  569 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  849
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel